-+ 0.00%
-+ 0.00%
-+ 0.00%

Curocell Seeks Approval to Amend Phase 3 Lymphoma Trial Plan

PUBT·10/30/2026 07:39:16
Listen to the news
Curocell Seeks Approval to Amend Phase 3 Lymphoma Trial Plan
  • Curocell applied to South Korea's MFDS on Oct. 30, 2026, for approval to amend its CRC01 Phase 3 trial plan.
  • The trial will compare CRC01 with standard treatment in approximately 136 adults with relapsed or refractory large B-cell lymphoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curocell Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030900803), on October 30, 2026, and is solely responsible for the information contained therein.